3 Psychiatry Headlines You Missed in June 2026

June brought regulatory setbacks, psychedelic breakthroughs, and a shifting neuromodulation landscape to psychiatry. Cingulate's once-daily ADHD therapy CTx-1301 hit a manufacturing-related snag at the US Food & Drug Administration (FDA), even as its phase 3 data across both adult and pediatric populations held up. Meanwhile, Definium Therapeutics' DT120 reported topline phase 3 results in treatment-resistant major depressive disorder (MDD), with a single dose producing rapid, durable symptom relief through 12 weeks; investigator John Sonnenberg, PhD, said this was unlike anything he's seen in his career.